Search

Displaying results 3301 - 3310 of 10000 in total
  1. Drug

    Patiromer

    go.drugbank.com/drugs/DB09263
    ApprovedInvestigational

    Patiromer sorbitex calcium is an amorphous, free-flowing powder that is composed of individual spherical beads. … Each gram of patiromer is equivalent to a nominal amount of 2 grams of patiromer sorbitex calcium.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    ATHX-105

    go.drugbank.com/drugs/DB06008
    Investigational

    ATHX-105 is an investigational selective 5HT2c receptor agonist developed by Athersys Inc. for the treatment of Obesity.

  3. Drug

    Luspatercept

    go.drugbank.com/drugs/DB12281
    ApprovedInvestigational

    Luspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1. … [A187835] Luspatercept's novel mechanism of action, then, is uniquely suited for the treatment of conditions in which late-stage erythropoiesis is defective, such as beta thalassemia and other myelodysplastic

  4. Drug

    Antilymphocyte immunoglobulin (horse)

    go.drugbank.com/drugs/DB09312
    ApprovedInvestigational

    It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. … The result is polyclonal IgG that is then purified from the horse's serum to produce a usable drug product that can be used for immunosuppression.

    Products: EQUAGAM 50 MG/ML İNFÜZYONLUK ÇÖZELTİ İÇEREN KONSANTRESİ, 5 ADET
  5. Drug

    Olokizumab

    go.drugbank.com/drugs/DB13127
    Investigational

    Interleukin-6 (IL-6) is an important cytokine with roles in immune cell proliferation/differentiation, energy and bone metabolism, and the acute phase response of the innate immune system. … [A241185, A241175] Olokizumab is a humanized anti-IL-6 IgG4κ antibody that directly blocks gp130 binding at IL-6 Site 3.[A241045]

  6. Drug

    Posizolid

    go.drugbank.com/drugs/DB04850
    Investigational

    Posizolid (AZD2563) is an oxazolidinone antibiotic. … In July 2002, after completion of phase I trials in December 2001, AstraZeneca announced that they were no longer pursuing the development of Posizolid, presumably due to negative trial results (though

  7. Drug

    DG051

    go.drugbank.com/drugs/DB05177
    Experimental

    DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and a potent promoter of inflammation. … DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack.

  8. Drug

    Acipimox

    go.drugbank.com/drugs/DB09055
    ApprovedInvestigational

    Flushing can be reduced by taking aspirin 20-30 min before taking Acipimox. High doses can cause disorders of liver function, impair glucose tolerance and precipitate gout. … Acipimox is a niacin derivative used as a hypolipidemic agent.

  9. Target

    Beta-ketoacyl-[acyl-carrier-protein] synthase III

    go.drugbank.com/bio_entities/BE0003868
    TargetEnterococcus faecalis (strain ATCC 700802 / V583)

    Catalyzes the condensation reaction of fatty acid synthesis by the addition to an acyl acceptor of two carbons from malonyl-ACP. Catalyzes the first condensation reaction which initiates fatty acid synthesis and may therefore play a role...

    Synonyms: KAS III
  10. Drug

    Itopride

    go.drugbank.com/drugs/DB04924
    Investigational

    Itopride is a dopamine D2 antagonist with acetylcholinesterase inhibitory actions.

    Products: ZİRİD 50 MG FİLM KAPLI TABLET, 40 ADET, ZİRİD 50 MG FİLM KAPLI TABLET, 100 ADET